← all drugs
Dexamethasone Sodium Phosphate Injection
in shortage · Dermatology · Snapshot: 2026-10-09
Day 2,800
of this shortage, counting from the FDA's first posting on 02/08/2019
- Manufacturers listed
- Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc., Mylan Institutional, a Viatris Company, Somerset Therapeutics, LLC, Eugia US LLC
- Reported reason(s)
- Demand increase for the drug
- Machine-readable
- JSON for this drug
Presentations (19)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) | Hikma Pharmaceuticals USA, Inc. | Available | 09/18/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) | Mylan Institutional, a Viatris Company | Available | 10/05/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) | Mylan Institutional, a Viatris Company | Available | 10/05/2026 |
| Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10) | Somerset Therapeutics, LLC | Available | 09/11/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) | Mylan Institutional, a Viatris Company | Available | 10/05/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25) | Eugia US LLC | Available | 10/02/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) | Hikma Pharmaceuticals USA, Inc. | Available | 09/18/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10) | Fresenius Kabi USA, LLC | Limited Availability | 09/15/2026 |
| Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25) | Somerset Therapeutics, LLC | Available | 09/11/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10) | Fresenius Kabi USA, LLC | Available | 10/06/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) | Hikma Pharmaceuticals USA, Inc. | Available | 09/18/2026 |
| Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10) | Fresenius Kabi USA, LLC | Limited Availability | 09/15/2026 |
| Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30) | Mylan Institutional, a Viatris Company | Available | 10/05/2026 |
History
Daily tracking of this drug began 2026-08-25 (the first day of the archive). No change to its FDA listing has been observed since.
Each daily snapshot is compared with the one before it; status changes, availability-wording revisions, and arrivals or removals are listed here. A change the FDA makes and reverses between two snapshots is not seen. Every daily record is kept in the public repository.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.